

Europäisches  
Patentamt

European Patent  
Office

F 01/EP2004 0004371

Office européen  
des brevets

**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b).



REC'D 16 SEP 2004  
WIPO PCT

**Bescheinigung**

**Certificate**

**Attestation**

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten internationalen Patentanmeldung überein.

The attached documents are exact copies of the International patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet international spécifiée à la page suivante.

Den Haag, den  
The Hague,  
La Haye, le

07.09.2004

Der Präsident des Europäischen Patentamts  
Im Auftrag  
For the President of the European Patent Office  
Le Président de l'Office européen des brevets  
p.o.


Cristina Iacoponi

Patentanmeldung Nr.  
Patent application no.  
Demande de brevet n°

PCT/EP 03/04492

**Best Available Copy**

**Blatt 2 der Bescheinigung**  
**Sheet 2 of the certificate**  
**Page 2 de l'attestation**



Anmeldung Nr.:  
 Application no.:  
 Demande n°:

PCT/EP 03/04492

Anmelder:  
 Applicant(s):  
 Demandeur(s):

1. ACTELION PHARMACEUTICALS LTD - Allschwil, Switzerland
2. BEZENCON, Olivier - Allschwil, Switzerland (US only)
3. BUR, Daniel - Therwil, Switzerland (US only)

Bezeichnung der Erfindung:  
 Title of the invention:  
 Titre de l'invention:

Novel 9-azabicyclononene Derivatives with a Heteroatom at the 3-position

Anmeldetag:  
 Date of filing:  
 Date de dépôt:

30 April 2003 (30.04.2003)

In Anspruch genommene Priorität(en)  
 Priority(ies) claimed  
 Priorité(s) revendiquée(s)

Staat:	Tag:	Aktenzeichen:
State:	Date:	File no.
Pays:	Date:	Numéro de dépôt:

Benennung von Vertragsstaaten : Siehe Formblatt PCT/RO/101 (beigefügt)  
 Designation of contracting states : See Form PCT/RO/101 (enclosed)  
 Désignation d'états contractants : Voir Formulaire PCT/RO/101 (ci-joint)

Bemerkungen:  
 Remarks:  
 Remarques:

Further applicant:

4. FISCHLI, Walter - Allschwil, Switzerland (US only)
5. REMEN, Lubos - Allschwil, Switzerland (US only)
6. RICHARD-BILDSTEIN, Sylvia - Rixheim, France (US only)
7. WELLER, Thomas - Binningen, Switzerland (US only)
8. SIFFERLEN, Thierry - Guewenheim, France (US only)

## PCT REQUEST

Original (for SUBMISSION) - printed on 28.04.2003 11:30:54 PM

III-7	<b>Applicant and/or inventor</b>	
III-7-1	This person is:	
III-7-2	Applicant for	
III-7-4	Name (LAST, First)	
III-7-5	Address:	
III-7-6	State of nationality	
III-7-7	State of residence	
IV-1	<b>Agent or common representative; or address for correspondence</b> The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:	
IV-1-1	Name (LAST, First)	
IV-1-2	Address:	
IV-1-3	Telephone No.	
IV-1-4	Facsimile No.	
IV-1-5	e-mail	
IV-1-5	Agent's registration No.	
V	<b>Designation of States</b>	
V-1	Regional Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	

AND/

applicant and inventor  
US only  
**SIFFERLEN, Thierry**  
6, rue de Thann  
F-68116 Guewenheim  
France

FR  
FR

agent

**HOFMANN, Dieter**  
StratAll  
Therwilerstrasse 87  
CH-4153 Reinach  
Switzerland

+41 61 713 1560  
+41 61 713 1561  
hofmann@bluewin.ch  
25510

AP: GH GM KE LS MW MZ SD SL SZ TZ UG ZM  
ZW and any other State which is a Contracting State of the Harare Protocol and of the PCT

EA: AM AZ BY KG KZ MD RU TJ TM and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT

EP: AT BE BG CH&LI CY CZ DE DK EE ES FI  
FR GB GR IE IT LU MC NL PT SE SK TR and any other State which is a Contracting State of the European Patent Convention and of the PCT,

OA: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG and any other State which is a member State of OAPI and a Contracting State of the PCT

ACTELION 40/R11

## Novel 9-azabicyclononene Derivatives with a Heteroatom at the 3-Position

5

The invention relates to novel compounds of the general formula I. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of formula I and especially their use as renin inhibitors in cardiovascular events and 10 renal insufficiency. Furthermore, these compounds can be regarded as inhibitors of other aspartyl proteases and might therefore be useful as inhibitors of plasmeprins to treat malaria and as inhibitors of *Candida albicans* secreted aspartyl proteases to treat fungal infections.

15 In the renin-angiotensin system (RAS) the biologically active angiotensin II (Ang II) is generated by a two-step mechanism. The highly specific enzyme renin cleaves angiotensinogen to angiotensin I (Ang I), which is then further processed to Ang II by the less specific angiotensin-converting enzyme (ACE). Ang II is known to work on at least two receptor subtypes called AT<sub>1</sub> and AT<sub>2</sub>. Whereas 20 AT<sub>1</sub> seems to transmit most of the known functions of Ang II, the role of AT<sub>2</sub> is still unknown.

Modulation of the RAS represents a major advance in the treatment of cardiovascular diseases. ACE inhibitors and AT<sub>1</sub> blockers have been accepted to 25 treat hypertension (Waeber B. et al., "The renin-angiotensin system: role in experimental and human hypertension", in Berkenhager W. H., Reid J. L. (eds): *Hypertension*, Amsterdam, Elsevier Science Publishing Co, 1996, 489-519; Weber M. A., *Am. J. Hypertens.*, 1992, 5, 247S). In addition, ACE inhibitors are used for renal protection (Rosenberg M. E. et al., *Kidney International*, 1994, 45, 30 403; Breyer J. A. et al., *Kidney International*, 1994, 45, S156), in the prevention of congestive heart failure (Vaughan D. E. et al., *Cardiovasc. Res.*, 1994, 28, 159;

Fouad-Tarazi F. *et al.*, *Am. J. Med.*, 1988, 84 (*Suppl. 3A*), 83) and myocardial infarction (Pfeffer M. A. *et al.*, *N. Engl. J. Med.*, 1992, 327, 669).

The rationale to develop renin inhibitors is the specificity of renin (Kleinert H. D.,  
5 *Cardiovasc. Drugs*, 1995, 9, 645). The only substrate known for renin is angiotensinogen, which can only be processed (under physiological conditions) by renin. In contrast, ACE can also cleave bradykinin besides Ang I and can be bypassed by chymase, a serine protease (Husain A., *J. Hypertens.*, 1993, 11, 1155). In patients inhibition of ACE thus leads to bradykinin accumulation causing  
10 cough (5-20%) and potentially life-threatening angioneurotic edema (0.1-0.2%) (Israeli Z. H. *et al.*, *Annals of Internal Medicine*, 1992, 117, 234). Chymase is not inhibited by ACE inhibitors. Therefore, the formation of Ang II is still possible in patients treated with ACE inhibitors. Blockade of the AT<sub>1</sub> receptor (e.g. by losartan) on the other hand overexposes other AT-receptor subtypes to Ang II,  
15 whose concentration is dramatically increased by the blockade of AT<sub>1</sub> receptors. This may raise serious questions regarding the safety and efficacy profile of AT<sub>1</sub> receptor antagonists. In summary, renin inhibitors are not only expected to be different from ACE inhibitors and AT<sub>1</sub> blockers with regard to safety, but more importantly also with regard to their efficacy to block the RAS.

20 Only limited clinical experience (Azizi M. *et al.*, *J. Hypertens.*, 1994, 12, 419; Neutel J. M. *et al.*, *Am. Heart*, 1991, 122, 1094) has been created with renin inhibitors because of their insufficient oral activity due to their peptidomimetic character (Kleinert H. D., *Cardiovasc. Drugs*, 1995, 9, 645). The clinical  
25 development of several compounds has been stopped because of this problem together with the high cost of goods. Only one compound containing four chiral centers has entered clinical trials (Rahuel J. *et al.*, *Chem. Biol.*, 2000, 7, 493; Mealy N. E., *Drugs of the Future*, 2001, 26, 1139). Thus, metabolically stable, orally bioavailable and sufficiently soluble renin inhibitors that can be prepared on  
30 a large scale are missing and sought. Recently, the first non-peptide renin inhibitors were described which show high *in vitro* activity (Oefner C. *et al.*, *Chem. Biol.*, 1999, 6, 127; Patent Application WO97/09311; Märki H. P. *et al.*, *II*

*Farmaco*, 2001, 56, 21). However, the development status of these compounds is not known.


The present invention relates to the identification of renin inhibitors of a non-peptidic nature and of low molecular weight. Orally active renin inhibitors of long duration of action which are active in indications beyond blood pressure regulation where the tissular renin-chymase system may be activated leading to pathophysiologically altered local functions such as renal, cardiac and vascular remodeling, atherosclerosis, and possibly restenosis are described.

10

The present invention describes non-peptidic renin inhibitors.

In particular, the present invention relates to novel compounds of the general formula I,

15



wherein

20 X independently represent -O-; -S-; -SO-; -SO<sub>2</sub>-;

W is a six-membered, non benzofused, phenyl or heteroaryl ring, substituted by V in position 3 or 4;

25 V represents a bond; -(CH<sub>2</sub>)<sub>r</sub>-; -A-(CH<sub>2</sub>)<sub>s</sub>-; -CH<sub>2</sub>-A-(CH<sub>2</sub>)<sub>t</sub>-; -(CH<sub>2</sub>)<sub>s</sub>-A-; -(CH<sub>2</sub>)<sub>2</sub>-A-(CH<sub>2</sub>)<sub>u</sub>-; -A-(CH<sub>2</sub>)<sub>v</sub>-B-; -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-A-CH<sub>2</sub>-; -A-CH<sub>2</sub>-CH<sub>2</sub>-B-CH<sub>2</sub>-; -CH<sub>2</sub>-

A-CH<sub>2</sub>-CH<sub>2</sub>-B-; -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-A-CH<sub>2</sub>-CH<sub>2</sub>-; -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-A-CH<sub>2</sub>-; -A-CH<sub>2</sub>-CH<sub>2</sub>-B-CH<sub>2</sub>-CH<sub>2</sub>-; -CH<sub>2</sub>-A-CH<sub>2</sub>-CH<sub>2</sub>-B-CH<sub>2</sub>-; -CH<sub>2</sub>-A-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-B-; or -CH<sub>2</sub>-CH<sub>2</sub>-A-CH<sub>2</sub>-CH<sub>2</sub>-B-; -O-CH<sub>2</sub>-CH(OCH<sub>3</sub>)-CH<sub>2</sub>-O-; -O-CH<sub>2</sub>-CH(CH<sub>3</sub>)-CH<sub>2</sub>-O-; -O-CH<sub>2</sub>-CH(CF<sub>3</sub>)-CH<sub>2</sub>-O-;

5

A and B independently represent -O-; -S-; -SO-; -SO<sub>2</sub>-;

U represents aryl; heteroaryl;

10 T represents -CONR<sup>1</sup>-; -(CH<sub>2</sub>)<sub>p</sub>OCO-; -(CH<sub>2</sub>)<sub>p</sub>N(R<sup>1</sup>)CO-; -(CH<sub>2</sub>)<sub>p</sub>N(R<sup>1</sup>)SO<sub>2</sub>-; or -COO-;

Q represents lower alkylene; lower alkenylene;

15 M represents hydrogen; cycloalkyl; aryl; heterocyclyl; heteroaryl;

R<sup>1</sup> represents hydrogen; lower alkyl; lower alkenyl; lower alkinyl; cycloalkyl; aryl; cycloalkyl - lower alkyl;

20 p is the integer 1, 2, 3 or 4;

r is the integer 3, 4, 5, or 6;

s is the integer 2, 3, 4, or 5;

t is the integer 1, 2, 3, or 4;

u is the integer 1, 2, or 3;

25 v is the integer 2, 3, or 4;

and optically pure enantiomers, mixtures of enantiomers such as racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, and the meso-form; as well as pharmaceutically acceptable salts, solvent complexes and morphological forms.

30

In the definitions of general formula I – if not otherwise stated – the term **lower alkyl**, alone or in combination with other groups, means saturated, straight and branched chain groups with one to seven carbon atoms, preferably one to four carbon atoms that can be optionally substituted by halogens. Examples of lower alkyl groups are methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, hexyl and heptyl. The methyl, ethyl nad isopropyl groups are preferred.

The term **lower alkoxy** refers to a R-O group, wherein R is a lower alkyl. Examples of lower alkoxy groups are methoxy, ethoxy, propoxy, iso-propoxy, iso-butoxy, sec-butoxy and tert-butoxy.

The term **lower alkenyl**, alone or in combination with other groups, means straight and branched chain groups comprising an olefinic bond and consisting of two to seven carbon atoms, preferably two to four carbon atoms, that can be optionally substituted by halogens. Examples of lower alkenyl are vinyl, propenyl or butenyl.

The term **lower alkinyl**, alone or in combination with other groups, means straight and branched chain groups comprising a triple bond and consisting of two to seven carbon atoms, preferably two to four carbon atoms, that can be optionally substituted by halogens. Examples of lower alkinyl are ethynyl, propynyl or butinyl.

The term **lower alkylene**, alone or in combination with other groups, means straight and branched divalent chain groups with one to seven carbon atoms, preferably one to four carbon atoms, that can be optionally substituted by halogens. Examples of lower alkylene are ethylene, propylene or butylene.

The term **lower alkenylene**, alone or in combination with other groups, means straight and branched divalent chain groups comprising an olefinic bond and consisting of two to seven carbon atoms, preferably two to four carbon atoms, that

can be optionally substituted by halogens. Examples of lower alkenylene are vinylene, propenylene and butenylene.

5 The term **lower alkylenedioxy**, refers to a lower alkylene substituted at each end by an oxygen atom. Examples of lower alkylenedioxy groups are preferably methylenedioxy and ethylenedioxy.

10 The term **lower alkyleneoxy** refers to a lower alkylene substituted at one end by an oxygen atom. Examples of lower alkyleneoxy groups are preferably methyleneoxy, ethyleneoxy and propyleneoxy.

The term **halogen** means fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine and bromine.

15 The term **cycloalkyl** alone or in combination, means a saturated cyclic hydrocarbon ring system with 3 to 7 carbon atoms, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, which can be optionally mono- or multisubstituted by lower alkyl, lower alkenyl, lower alkenylene, lower alkoxy, lower alkyleneoxy, lower alkylenedioxy, hydroxy, halogen,  $-CF_3$ ,  $-NR^1R^1'$ ,  $-NR^1C(O)R^1'$ ,  $-NR^1S(O_2)R^1'$ ,  $-C(O)NR^1R^1'$ , lower alkylcarbonyl,  $-COOR^1$ ,  $-SR^1$ ,  $-SOR^1$ ,  $-SO_2R^1$ ,  $-SO_2NR^1R^1'$  whereby  $R^1'$  represents hydrogen; lower alkyl; lower alkenyl; lower alkinyl; cycloalkyl; aryl; cycloalkyl - lower alkyl. The cyclopropyl group is a preferred group.

25 The term **aryl**, alone or in combination, relates to the phenyl, the naphthyl or the indanyl group, preferably the phenyl group, which can be optionally mono- or multisubstituted by lower alkyl, lower alkenyl, lower alkinyl, lower alkenylene or lower alkylene forming with the aryl ring a five- or six-membered ring, lower alkoxy, lower alkylenedioxy, lower alkyleneoxy, hydroxy, hydroxy-lower alkyl, halogen, cyano,  $-CF_3$ ,  $-OCF_3$ ,  $-NR^1R^1'$ ,  $-NR^1R^1'$  - lower alkyl,  $-NR^1C(O)R^1'$ ,  $-NR^1S(O_2)R^1'$ ,  $-C(O)NR^1R^1'$ ,  $-NO_2$ , lower alkylcarbonyl,  $-COOR^1$ ,  $-SR^1$ ,  $-SOR^1$ ,

-SO<sub>2</sub>R<sup>1</sup>, -SO<sub>2</sub>NR<sup>1</sup>R<sup>1'</sup>, benzyloxy, whereby R<sup>1'</sup> has the meaning given above. Preferred substituents are halogen, lower alkoxy, lower alkyl, CF<sub>3</sub>, OCF<sub>3</sub>.

The term **aryloxy** refers to an Ar-O group, wherein Ar is an aryl. An example of  
5 a lower aryloxy group is phenoxy.

The term **heterocycl**, alone or in combination, means saturated or unsaturated (but not aromatic) five-, six- or seven-membered rings containing one or two nitrogen, oxygen or sulfur atoms which may be the same or different and which  
10 rings can be optionally substituted with lower alkyl, hydroxy, lower alkoxy and halogen. The nitrogen atoms, if present, can be substituted by a -COOR<sup>2</sup> group. Examples of such rings are piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, tetrahydropyranyl, dihydropyranyl, 1,4-dioxanyl, pyrrolidinyl, tetrahydrofuranyl, dihydropyrrolyl, imidazolidinyl, dihydropyrazolyl,  
15 pyrazolidinyl, dihydroquinolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl.

The term **heteroaryl**, alone or in combination, means six-membered aromatic rings containing one to four nitrogen atoms; benzofused six-membered aromatic rings containing one to three nitrogen atoms; five-membered aromatic rings containing one oxygen, one nitrogen or one sulfur atom; benzofused five-membered aromatic rings containing one oxygen, one nitrogen or one sulfur atom; five-membered aromatic rings containing one oxygen and one nitrogen atom and benzofused derivatives thereof; five-membered aromatic rings containing a sulfur and a nitrogen or an oxygen atom and benzofused derivatives thereof; five-membered aromatic rings containing two nitrogen atoms and benzofused derivatives thereof; five-membered aromatic rings containing three nitrogen atoms and benzofused derivatives thereof, or a tetrazolyl ring. Examples of such ring systems are furanyl, thiophenyl, pyrrolyl, pyridinyl, pyrimidinyl, indolyl, quinolinyl, isoquinolinyl, imidazolyl, triazinyl, thiazinyl, thiazolyl, isothiazolyl,  
20 pyridazinyl, pyrazolyl, oxazolyl, isoxazolyl, coumarinyl, benzothiophenyl, quinazolinyl, quinoxalinyl. Such rings may be adequately substituted with lower alkyl, lower alkenyl, lower alkinyl, lower alkylene, lower alkenylene, lower  
25

alkylenedioxy, lower alkyleneoxy, hydroxy-lower alkyl, lower alkoxy, hydroxy, halogen, cyano, -CF<sub>3</sub>, -OCF<sub>3</sub>, -NR<sup>1</sup>R<sup>1</sup>, -NR<sup>1</sup>R<sup>1</sup> - lower alkyl, -N(R<sup>1</sup>)COR<sup>1</sup>, -N(R<sup>1</sup>)SO<sub>2</sub>R<sup>1</sup>, -CONR<sup>1</sup>R<sup>1</sup>, -NO<sub>2</sub>, lower alkylcarbonyl, -COOR<sup>1</sup>, -SR<sup>1</sup>, -SOR<sup>1</sup>, -SO<sub>2</sub>R<sup>1</sup>, -SO<sub>2</sub>NR<sup>1</sup>R<sup>1</sup>, another aryl, another heteroaryl or another heterocyclyl and  
5 the like, whereby R<sup>1</sup> has the meaning given above. Preferred heteroaryl are pyridinyl, pirimidinyl, pirazinyl.

The term **heteroaryloxy** refers to a Het-O group, wherein Het is a heteroaryl.

10 The expression **pharmaceutically acceptable salts** encompasses either salts with inorganic acids or organic acids like hydrochloric or hydrobromic acid, sulfuric acid, phosphoric acid, citric acid, formic acid, acetic acid, maleic acid, tartaric acid, benzoic acid, methanesulfonic acid, p-toluenesulfonic acid, and the like that are non toxic to living organisms or in case the compound of formula I is acidic in  
15 nature with an inorganic base like an alkali or earth alkali base, e.g. sodium hydroxide, potassium hydroxide, calcium hydroxide and the like.

The compounds of the general formula I can contain two or more asymmetric carbon atoms and may be prepared in form of optically pure enantiomers,  
20 mixtures of enantiomers such as racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, and the meso-form and pharmaceutically acceptable salts therof.

The present invention encompasses all these forms. Mixtures may be separated in a manner known *per se*, i.e. by column chromatography, thin layer chromatography, HPLC or crystallization.  
25

A group of preferred compounds of general formula I above are those wherein X, W, V, and U are as defined in general formula I and

30 T is -CONR<sup>1</sup>-;  
Q is methylene;  
M is hydrogen; aryl; or heteroaryl.

Another group of even more preferred compounds of general formula I are those wherein X, W, U, T, Q, and M are as defined in general formula I above and

5 V is -CH<sub>2</sub>CH<sub>2</sub>O-; -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>O-; -OCH<sub>2</sub>CH<sub>2</sub>O-.

Another group of also more preferred compounds of general formula I are those wherein V, U, T, Q, and M are as defined in general formula I above and

10 W represent a 1,4-disubstituted phenyl group.

Another group of also more preferred compounds of general formula I are those wherein X, W, V, U, T, Q, and M are as defined in general formula I above and

15 U is a mono-, di-, or trisubstituted phenyl wherein the substituents are halogen; lower alkyl or lower alkoxy.

Especially preferred compounds of general formula I are those selected from the group consisting of:

20 (*rac.*)-(1*R*, 5*S*)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxa-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dimethylbenzyl)-amide,

25 (*rac.*)-(1*R*, 5*S*)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dimethylbenzyl)-amide, and

30 (*rac.*)-(1*R*, 5*S*)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3,3-dioxo-3*λ*<sup>6</sup>-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dimethylbenzyl)amide.

The compounds of general formula I and their pharmaceutically acceptable salts may be used as therapeutics e.g. in form of pharmaceutical compositions. They may especially be used in the treatment and/or prophylaxis of cardiovascular and renal diseases. Examples of such diseases are hypertension, coronary diseases, 5 cardiac insufficiency, renal insufficiency, renal and myocardial ischemia, and renal failure. They can also be used to prevent restenosis after balloon or stent angioplasty, to treat erectile dysfunction, glomerulonephritis, renal colic, and glaucoma. Furthermore, they can be used in the therapy and the prophylaxis of diabetic complications, complications of vascular or cardiac surgery or after organ 10 transplantation, complications of cyclosporin treatment, as well as other diseases presently known to be related to the RAS.

In another embodiment, the invention relates to a method for the treatment and/or prophylaxis of diseases which are related to the RAS such as hypertension, 15 coronary diseases, cardiac insufficiency, renal insufficiency, renal and myocardial ischemia, and renal failure, which method comprises administrating a compound as defined above to a human being or animal.

The invention further relates to the use of compounds of general formula I as 20 defined above for the treatment and/or prophylaxis of diseases which are associated with the RAS such as hypertension, coronary diseases, cardiac insufficiency, renal insufficiency, renal and myocardial ischemia, and renal failure.

25 In addition, the invention relates to the use of compounds as defined above for the preparation of medicaments for the treatment and/or prophylaxis of diseases which are associated with the RAS such as hypertension, coronary diseases, cardiac insufficiency, renal insufficiency, renal and myocardial ischemia, and renal failure.

30 The compounds of formula I may also be used in combination with one or more other therapeutically useful substances e. g. with other renin inhibitors, with ACE-

inhibitors, with angiotensin-receptor antagonists, with diuretics, with calcium channel blockers, with endothelin receptors antagonists or with other drugs beneficial for the prevention or the treatment of cardiovascular events or renal insufficiency.

5


All forms of prodrugs leading to an active component comprised by general formula I above are included in the present invention.

The compounds of general formula I can be manufactured by the methods  
10 outlined below, by the methods described in the examples or by analogous methods.

### Chemistry

15 Bicyclic systems of type A (Scheme 1; Jerchel, D; *et al.*; *Justus Liebigs Ann. Chem.*, 1957, 607, 126; Zirkle, C. L.; *et al.*; *J. Org. Chem.*, 1961, 26, 395) can be used as starting material. A stereoselective or a racemic acylation (Majewski, M; *et al.*; *J. Org. Chem.*, 1995, 60, 5825) may yield a bicyclic compound of type B. These compounds may be then converted into the corresponding vinyl triflates C,  
20 then a carbon-carbon coupling, typically catalyzed by a Pd-complex, may lead to a derivative of type D. Protecting group manipulation may lead to a bicyclic system of type E, and standard manipulations, like deprotection and *Mitsunobu* coupling, can lead to bicyclic compounds of type F. Hydrolysis of the ester may lead to compounds of type G, then an amide coupling for instance to bicyclic compounds  
25 of type H. If X is a sulfur atom, it may be oxidized to a sulfoxide or a sulfone (→ compounds of type J), then deprotection may lead to the final compounds if type K.

Scheme 1



The compounds of formula I and their pharmaceutically acceptable acid addition salts can be used as medicaments, e. g. in the form of pharmaceutical preparations for enteral, parenteral, or topical administration. They can be administered, for example, perorally, e. g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions, rectally, e. g. in the form of suppositories, parenterally, e. g. in the form of injection solutions or infusion solutions, or topically, e. g. in the form of ointments, creams or oils.

10 The production of pharmaceutical preparations can be effected in a manner which will be familiar to any person skilled in the art by bringing the described compounds of formula I and their pharmaceutically acceptable acid addition salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, 15 therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.

Suitable carrier materials are not only inorganic carrier materials, but also organic carrier materials. Thus, for example, lactose, corn starch or derivatives thereof, 20 talc, stearic acid or its salts can be used as carrier materials for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carrier materials for soft gelatine capsules are, for example, vegetable oils, waxes, fats and semi-solid and liquid polyols (depending on the nature of the active ingredient no carriers are, however, required in the case of soft gelatine capsules). Suitable carrier materials 25 for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar and the like. Suitable carrier materials for injections are, for example, water, alcohols, polyols, glycerols and vegetable oils. Suitable carrier materials for suppositories are, for example, natural or hardened oils, waxes, fats and semi-liquid or liquid polyols. Suitable carrier materials for topical 30 preparations are glycerides, semi-synthetic and synthetic glycerides, hydrogenated oils, liquid waxes, liquid paraffins, liquid fatty alcohols, sterols, polyethylene glycols and cellulose derivatives.

Usual stabilizers, preservatives, wetting and emulsifying agents, consistency-improving agents, flavour-improving agents, salts for varying the osmotic pressure, buffer substances, solubilizers, colorants and masking agents and 5 antioxidants come into consideration as pharmaceutical adjuvants.

The dosage of compounds of formula I can vary within wide limits depending on the disease to be controlled, the age and the individual condition of the patient and the mode of administration, and will, of course, be fitted to the individual 10 requirements in each particular case. For adult patients a daily dosage of about 1 mg to about 1000 mg, especially about 50 mg to about 500 mg, comes into consideration.

15 The pharmaceutical preparations conveniently contain about 1 - 500 mg, preferably 5 - 200 mg of a compound of formula I.

The following examples serve to illustrate the present invention in more detail. They are, however, not intended to limit its scope in any manner.

## 20 Examples

### Abbreviations

25	ACE	Angiotensin Converting Enzyme
	AcOH	Acetic acid
	Ang	Angiotensin
	aq.	aqueous

	Bn	Benzyl
	Boc	<i>tert</i> -Butyloxycarbonyl
	BSA	Bovine serum albumine
	BuLi	<i>n</i> -Butyllithium
5	conc.	concentrated
	DIPEA	Diisopropylethylamine
	DMAP	4- <i>N,N</i> -Dimethylaminopyridine
	DMSO	Dimethylsulfoxide
	EDC·HCl	Ethyl- <i>N,N</i> -dimethylaminopropylcarbodiimide hydrochloride
10	EIA	Enzyme immunoassay
	eq.	equivalent
	Et	Ethyl
	EtOAc	Ethyl acetate
	FC	Flash Chromatography
15	HOBt	Hydroxybenzotriazol
	KHMDS	Potassium hexamethyldisilazide
	MeOH	Methanol
	org.	organic
	PG	protecting group
20	Ph	Phenyl
	RAS	Renin Angiotensin System
	RP18	Reversed phase column, filled with C <sub>18</sub> hydrocarbon
	rt	room temperature
	sol.	Solution
25	TBAF	Tetra- <i>n</i> -butylammonium fluoride
	TBDMS	<i>tert</i> -Butyldimethylsilyl
	Tf	Trifluoromethylsulfonyl
	THF	Tetrahydrofuran
	TLC	Thin Layer Chromatography

## Precursors

**(*rac.*)-(1*R*, 5*S*)-9-Methyl-7-oxo-3-oxa-9-azabicyclo[3.3.1]nonane-6-carboxylic acid methyl ester (B1)**

A sol. of LDA was prepared from diisopropylamine (6.67 mL, 48 mmol), BuLi (1.6 M in hexanes, 31.9 mL, 51 mmol) and THF (150 mL). This sol. was cooled to -78 °C and a sol. of 9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-one A1 (7.14 g, 46.0 mmol) in THF (10 mL) was added dropwise over 3 min. The reaction mixture was stirred for 3 h at -78 °C, then benzylcyanoformat (14.8 g, 92.0 mmol) was added. The reaction mixture was stirred for 30 min. at -78 °C and a sol. of AgNO<sub>3</sub> (19.1 g, 112 mmol) in H<sub>2</sub>O/THF (1:1, 200 mL) was added. After 10 min, H<sub>2</sub>O (150 mL) and AcOH (150 mL) were added and the reaction mixture was allowed to warm to rt. Ammoniac (25% in water) was added until the Ag-salt had completely dissolved. The reaction mixture was extracted with EtOAc (1x) and CH<sub>2</sub>Cl<sub>2</sub> (2x). The combined org. extracts were dried over MgSO<sub>4</sub> and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title compound.

**(*rac.*)-(1*R*, 5*S*)-9-Methyl-7-oxo-3-thia-9-azabicyclo[3.3.1]nonane-6-carboxylic acid methyl ester (B2)**

A sol. of LDA was prepared from diisopropylamine (6.67 mL, 48 mmol), BuLi (1.6 M in hexanes, 31.9 mL, 51 mmol) and THF (150 mL). This sol. was cooled to -78 °C and a sol. of 9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-one A2 (7.88 g, 46.0 mmol) in THF (10 mL) was added dropwise over 3 min. The reaction mixture was stirred for 3 h at -78 °C, then benzylcyanoformat (14.8 g, 92.0 mmol) was added. The reaction mixture was stirred for 30 min. at -78 °C and a sol. of AgNO<sub>3</sub> (19.1 g, 112 mmol) in H<sub>2</sub>O/THF (1:1, 200 mL) was added. After 10 min, H<sub>2</sub>O (150 mL) and AcOH (150 mL) were added and the reaction mixture was allowed to warm to rt. Ammoniac (25% in water) was added until the Ag-salt had completely dissolved. The reaction mixture was extracted with EtOAc (1x) and CH<sub>2</sub>Cl<sub>2</sub> (2x). The combined org. extracts were dried over MgSO<sub>4</sub> and the solvents

were removed under reduced pressure. Purification of the residue by FC yielded the title compound.

*(rac.)-(1R, 5S)-9-Methyl-7-trifluoromethanesulfonyloxy-3-oxa-9-aza-*

*bicyclo[3.3.1]non-6-ene-6-carboxylic acid methyl ester (C1)*

A sol. of bicyclonanonone **B1** (7.46 g, 35.0 mmol) in THF (250 mL) was cooled to 0 °C and NaH (about 60% in mineral oil, 1.78 g, about 45 mmol) was added. A gas evolution was observed. After 20 min, Tf<sub>2</sub>NPh (17.5 g, 49.1 mmol) was added. 10 min later, the ice bath was removed. The sol. was stirred overnight, and diluted with EtOAc and washed with brine (1x). The org. extracts were dried over MgSO<sub>4</sub>, filtered, and the solvents were removed under reduced pressure. Purification by FC yielded the title compound as an oil.

*15 (rac.)-(1R, 5S)-9-Methyl-7-trifluoromethanesulfonyloxy-3-thia-9-aza-*

*bicyclo[3.3.1]non-6-ene-6-carboxylic acid methyl ester (C2)*

A sol. of bicyclonanonone **B2** (8.03 g, 35.0 mmol) in THF (250 mL) was cooled to 0 °C and NaH (about 60% in mineral oil, 1.78 g, about 45 mmol) was added. A gas evolution was observed. After 20 min, Tf<sub>2</sub>NPh (17.5 g, 49.1 mmol) was added. 10 min later, the ice bath was removed. The sol. was stirred overnight, and diluted with EtOAc and washed with brine (1x). The org. extracts were dried over MgSO<sub>4</sub>, filtered, and the solvents were removed under reduced pressure. Purification by FC yielded the title compound as an oil.

25

*(rac.)-(1R, 5S)-7-{4-[3-(*tert*-Butyldimethylsilyloxy)propyl]phenyl}-9-*

*methyl-3-oxa-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid methyl ester*

**(D1)**

30 A sol. of [3-(4-bromophenyl)propoxy]-*tert*-butyldimethylsilane (Kiesewetter D. O., *Tetrahedron Asymmetry*, 1993, 4, 2183, 24.50 g, 74.4 mmol) in THF (450 mL) was cooled to -78 °C. BuLi (1.6M in hexane, 48.8 mL, 78.0 mmol) was added.

After 30 min, ZnCl<sub>2</sub> (1M in THF, 80 mL, 80 mmol, prepared from ZnCl<sub>2</sub> dried overnight at 150 °C and THF) was added. The mixture was allowed to warm up to rt. Vinyl triflate C1 (10.2 g, 29.7 mmol) in THF (20 mL) and then Pd(PPh<sub>3</sub>)<sub>4</sub> (600 mg, 0.519 mmol) were added. The mixture was heated to reflux for 90 min and aq. 1M HCl (1 mL) was added. The mixture was diluted with EtOAc and washed with aq. 1M NaOH (1x). The org. extracts were dried over MgSO<sub>4</sub>, filtered and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title product.

(rac.)-(*1R*, 5*S*)-7-{4-[3-(*tert*-Butyldimethylsilyloxy)propyl]phenyl}-9-methyl-3-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid methyl ester (D2)

A sol. of [3-(4-bromophenyl)propoxy]-*tert*-butyldimethylsilane (Kiesewetter D. O., *Tetrahedron Asymmetry*, 1993, 4, 2183, 24.50 g, 74.4 mmol) in THF (450 mL) was cooled to -78 °C. BuLi (1.6M in hexane, 48.8 mL, 78.0 mmol) was added. After 30 min, ZnCl<sub>2</sub> (1M in THF, 80 mL, 80 mmol, prepared from ZnCl<sub>2</sub> dried overnight at 150 °C and THF) was added. The mixture was allowed to warm up to rt. Vinyl triflate C2 (10.7 g, 29.7 mmol) in THF (20 mL) and then Pd(PPh<sub>3</sub>)<sub>4</sub> (600 mg, 0.519 mmol) were added. The mixture was heated to reflux for 90 min and aq. 1M HCl (1 mL) was added. The mixture was diluted with EtOAc and washed with aq. 1M NaOH (1x). The org. extracts were dried over MgSO<sub>4</sub>, filtered and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title product.

(*rac.*)-(1*R*, 5*S*)-7-{4-[3-(*tert*-Butyldimethylsilyloxy)propyl]phenyl}-3-oxa-9-azabicyclo[3.3.1]non-6-ene-6,9-dicarboxylic acid 9-*tert*-butyl ester 6-methyl ester (E1)

2-Chloroethyl chloroformate (19.1g, 133.7 mmol) was added to a sol. of bicyclononene D1 (11.9 g, 26.7 mmol) in 1,2-dichloroethane (300 mL). The sol. was heated to reflux. After 4 h, the reaction mixture was allowed to cool to rt, and

MeOH (100 mL) was added. The mixture was stirred at rt for 4 h, and the solvents were removed under reduced pressure. The residue was diluted with EtOAc and washed with aq. 1M NaOH (2x). The org. extracts were dried over MgSO<sub>4</sub>, filtered, and the solvents were removed under reduced pressure. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (100 mL), DIPEA (8.20 mL, 48.0 mmol) was added, and the mixture was cooled to 0 °C. Boc<sub>2</sub>O (5.86 g, 26.0 mmol) was added and the mixture was stirred at 0 °C for 1 h, then at rt for 2 h. The mixture was washed with aq. 1M HCl (1x), and aq. sat. NaHCO<sub>3</sub> (1x). The org. extracts were dried over MgSO<sub>4</sub>, filtered, and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title compound.

**(rac.)-(1*R*, 5*S*)-7-[4-(3-Hydroxypropyl)phenyl]-3-oxa-9-azabicyclo[3.3.1]non-6-ene-6,9-dicarboxylic acid 9-*tert*-butyl ester 6-methyl ester (E2)**

TBAF (1M in THF, 30.0 mL, 30.0 mmol) was added to a sol. of bicyclononene E1 (10.6 g, 20.0 mmol) in THF (200 mL) at 0 °C. The mixture was stirred for 1 h at 0 °C, then for 3 h at rt. The mixture was diluted with EtOAc and washed with brine (2x). The org. extracts were dried over MgSO<sub>4</sub>, filtered, and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title compound.

**(rac.)-(1*R*, 5*S*)-7-{4-[3-(*tert*-Butyldimethylsilyloxy)propyl]phenyl}-3-thia-9-azabicyclo[3.3.1]non-6-ene-6,9-dicarboxylic acid 9-*tert*-butyl ester 6-methyl ester (E3)**

2-Chloroethyl chloroformate (19.1g, 133.7 mmol) was added to a sol. of bicyclononene D2 (12.3 g, 26.7 mmol) in 1,2-dichloroethane (300 mL). The sol. was heated to reflux. After 4 h, the reaction mixture was allowed to cool to rt, and MeOH (100 mL) was added. The mixture was stirred at rt for 4 h, and the solvents were removed under reduced pressure. The residue was diluted with EtOAc and washed with aq. 1M NaOH (2x). The org. extracts were dried over MgSO<sub>4</sub>, filtered, and the solvents were removed under reduced pressure. The

residue was dissolved in  $\text{CH}_2\text{Cl}_2$  (100 mL), DIPEA (8.20 mL, 48.0 mmol) was added, and the mixture was cooled to 0 °C.  $\text{Boc}_2\text{O}$  (5.86 g, 26.0 mmol) was added and the mixture was stirred at 0 °C for 1 h, then at rt for 2 h. The mixture was washed with aq. 1M HCl (1x), and aq. sat.  $\text{NaHCO}_3$  (1x). The org. extracts were dried over  $\text{MgSO}_4$ , filtered, and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title compound.

**(*rac.*)-(1*R*, 5*S*)-7-[4-(3-Hydroxypropyl)phenyl]-3-thia-9-azabicyclo[3.3.1]non-6-ene-6,9-dicarboxylic acid 9-*tert*-butyl ester 6-methyl ester (E4)**

TBAF (1M in THF, 30.0 mL, 30.0 mmol) was added to a sol. of bicyclononene E3 (10.96 g, 20.0 mmol) in THF (200 mL) at 0 °C. The mixture was stirred for 1 h at 0 °C, then for 3 h at rt. The mixture was diluted with EtOAc and washed with brine (2x). The org. extracts were dried over  $\text{MgSO}_4$ , filtered, and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title compound.

**(*rac.*)-(1*R*, 5*S*)-7-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxa-9-azabicyclo[3.3.1]non-6-ene-6,9-dicarboxylic acid 9-*tert*-butyl ester 6-methyl ester (F1)**

Tributylphosphine (11.1 mL, 45.0 mmol) was added to a sol. of bicyclononene E2 (6.26 g, 15.0 mmol), 2-chloro-3,6-difluorophenol (4.95 g, 30.0 mmol) and azodicarboxylic dipiperidine (7.58 g, 30.0 mmol) in toluene (100 mL). The mixture was heated to reflux for 2 h and allowed to cool to rt. The solvents were removed under reduced pressure. Purification by FC yielded the title compound.

**(*rac.*)-(1*R*, 5*S*)-7-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]phenyl}-3-thia-9-azabicyclo[3.3.1]non-6-ene-6,9-dicarboxylic acid 9-*tert*-butyl ester 6-methyl ester (F2)**

Tributylphosphine (11.1 mL, 45.0 mmol) was added to a sol. of bicyclononene **E4** (6.50 g, 15.0 mmol), 2-chloro-3,6-difluorophenol (4.95 g, 30.0 mmol) and azodicarboxylic dipiperide (7.58 g, 30.0 mmol) in toluene (100 mL). The mixture was heated to reflux for 2 h and allowed to cool to rt. The solvents were  
5 removed under reduced pressure. Purification by FC yielded the title compound.

**(*rac.*)-(1*R*, 5*S*)-7-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxa-9-azabicyclo[3.3.1]non-6-ene-6,9-dicarboxylic acid 9-*tert*-butyl ester (G1)**

10 Bicyclononene **F1** (7.78 g, 13.8 mmol) was dissolved in EtOH (300 mL). Aq. 1M NaOH (300 mL) was added and the mixture was heated to 80 °C. The sol. was stirred for 5 h at 80 °C, then allowed to cool down to rt. After acidification to pH = 1-2 with aq. 1M HCl the mixture was extracted with EtOAc (3x). The combined org. extracts were dried over MgSO<sub>4</sub>, filtered and the solvents were  
15 removed under reduced pressure. Purification of the residue by FC yielded the title compound.

**(*rac.*)-(1*R*, 5*S*)-7-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]phenyl}-3-thia-9-azabicyclo[3.3.1]non-6-ene-6,9-dicarboxylic acid 9-*tert*-butyl ester (G2)**

20 Bicyclononene **F2** (8.00 g, 13.8 mmol) was dissolved in EtOH (300 mL). Aq. 1M NaOH (300 mL) was added and the mixture was heated to 80 °C. The sol. was stirred for 5 h at 80 °C, then allowed to cool down to rt. After acidification to pH = 1-2 with aq. 1M HCl the mixture was extracted with EtOAc (3x). The  
25 combined org. extracts were dried over MgSO<sub>4</sub>, filtered and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title compound.

30 **(*rac.*)-(1*R*, 5*S*)-7-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]phenyl}-6-[cyclopropyl-(2,3-dimethylbenzyl)carbamoyl]-3-oxa-9-azabicyclo[3.3.1]non-6-ene-9-carboxylic acid *tert*-butyl ester (H1)**

A mixture of bicyclononene **G1** (1.10 g, 2.00 mmol), cyclopropyl-(2,3-dimethylbenzyl)amine (1.05 g, 6.00 mmol), DIPEA (1.37 mL, 8.00 mmol), DMAP (61 mg, 0.50 mmol), HOBr (149 mg, 1.10 mmol) and EDC·HCl (1.19 g, 6.00 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was stirred at rt for 3 days. The mixture was diluted with more CH<sub>2</sub>Cl<sub>2</sub>, and washed with aq. 1M HCl (3x) and aq. sat. NaHCO<sub>3</sub> (1x). The org. extracts were dried over MgSO<sub>4</sub>, filtered, and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title compound.

5                             (rac.)-(*1R*,                *5S*)-7-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]phenyl}-6-  
10                             [cyclopropyl-(2,3-dimethylbenzyl)carbamoyl]-3-thia-9-azabicyclo[3.3.1]non-  
6-ene-9-carboxylic acid *tert*-butyl ester (**H2**)

A mixture of bicyclononene **G2** (2.26 g, 4.00 mmol), cyclopropyl-(2,3-dimethylbenzyl)amine (2.10 g, 12.0 mmol), DIPEA (2.74 mL, 16.0 mmol), DMAP (122 mg, 1.00 mmol), HOBr (298 mg, 2.20 mmol) and EDC·HCl (2.40 g, 12.0 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was stirred at rt for 3 days. The mixture was diluted with more CH<sub>2</sub>Cl<sub>2</sub>, and washed with aq. 1M HCl (3x) and aq. sat. NaHCO<sub>3</sub> (1x). The org. extracts were dried over MgSO<sub>4</sub>, filtered, and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title compound.

20                             (rac.)-(*1R*,                *5S*)-7-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]phenyl}-6-  
[cyclopropyl-(2,3-dimethylbenzyl)carbamoyl]-3,3-dioxo-3*λ*<sup>6</sup>-thia-9-azabi-  
cyclo[3.3.1]non-6-ene-9-carboxylic acid *tert*-butyl ester (**J**)

25                             3-Chloro-perbenzoic acid (692 mg, 4.00 mmol) was added to a sol. of bicyclononene **H2** (723 mg, 1.00 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) at 0 °C. The mixture was stirred at rt overnight and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title compound.

## 30                             **Examples**

### Example 1

*(rac.)-(1R, 5S)-7-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxa-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dimethylbenzyl)amide*

5

Bicyclononene **H1** was diluted with CH<sub>2</sub>Cl<sub>2</sub> (10 mL) and the mixture was cooled to 0 °C. HCl (4M in dioxane, 10 mL) was added and the mixture was stirred for 1 h at 0 °C, then 1h at rt. The solvents were removed under reduced pressure and the residue was dried under high vacuum. The residue was diluted with CH<sub>2</sub>Cl<sub>2</sub> and washed with aq. 1M NaOH until the org. phase had a pH > 9. The org. extracts wer dried over MgSO<sub>4</sub>, filtered, and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title compound.

### Example 2

15

*(rac.)-(1R, 5S)-7-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]phenyl}-3-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dimethylbenzyl)amide*

Bicyclononene **H2** was diluted with CH<sub>2</sub>Cl<sub>2</sub> (10 mL) and the mixture was cooled to 0 °C. HCl (4M in dioxane, 10 mL) was added and the mixture was stirred for 1 h at 0 °C, then 1h at rt. The solvents were removed under reduced pressure and the residue was dried under high vacuum. The residue was diluted with CH<sub>2</sub>Cl<sub>2</sub> and washed with aq. 1M NaOH until the org. phase had a pH > 9. The org. extracts wer dried over MgSO<sub>4</sub>, filtered, and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title compound.

### Example 3

*(rac.)-(1R, 5S)-7-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]phenyl}-3,3-dioxo-3λ<sup>6</sup>-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dimethylbenzyl)amide*

Bicyclononene J was diluted with CH<sub>2</sub>Cl<sub>2</sub> (10 mL) and the mixture was cooled to 0 °C. HCl (4M in dioxane, 10 mL) was added and the mixture was stirred for 1 h at 0 °C, then 1h at rt. The solvents were removed under reduced pressure and the residue was dried under high vacuum. The residue was diluted with CH<sub>2</sub>Cl<sub>2</sub> and washed with aq. 1M NaOH until the org. phase had a pH > 9. The org. extracts were dried over MgSO<sub>4</sub>, filtered, and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title compound.

10 **Inhibition of human recombinant renin by the compounds of the invention**

The enzymatic in vitro assay was performed in 384-well polypropylene plates (Nunc). The assay buffer consisted of 10 mM PBS (Gibco BRL) including 1 mM EDTA and 0.1% BSA. The incubates were composed of 50 µL per well of an enzyme mix and 2.5 µL of renin inhibitors in DMSO. The enzyme mix was premixed at 4°C and consists of the following components:

- 15 • human recombinant renin (0.16 ng/mL)
- synthetic human angiotensin(1-14) (0.5 µM)
- 20 • hydroxyquinoline sulfate (1 mM)


The mixtures were then incubated at 37°C for 3 h.

To determine the enzymatic activity and its inhibition, the accumulated Ang I was detected by an enzyme immunoassay (EIA) in 384-well plates (Nunc). 5 µL of the incubates or standards were transferred to immuno plates which were previously coated with a covalent complex of Ang I and bovine serum albumin (Ang I - BSA). 75 µL of Ang I-antibodies in essaybuffer above including 0.01% Tween 20 were added and a primary incubation made at 4 °C overnight. The plates were washed 3 times with PBS including 0.01% Tween 20, and then incubated for 2 h at rt with an antirabbit-peroxidase coupled antibody (WA 934, Amersham). After washing the plates 3 times, the *peroxidase substrate* ABTS (2,2'-azino-di-(3-ethylbenzthiazolinsulfonate), was added and the plates incubated for 60 min at room temperature. After stopping the reaction with 0.1 M citric acid pH 4.3 the plate

was evaluated in a microplate reader at 405 nm. The percentage of inhibition was calculated of each concentration point and the concentration of renin inhibition was determined that inhibited the enzyme activity by 50% ( $IC_{50}$ ). The  $IC_{50}$ -values of all compounds tested are below 100 nM. However selected compounds exhibit  
5 a very good bioavailability and are metabolically more stable than prior art compounds.

## Claims

1. Compounds of the general formula I



5

wherein

X independently represent -O-; -S-; -SO-; -SO<sub>2</sub>-;

10

W is a six-membered, non benzofused, phenyl or heteroaryl ring, substituted by V in position 3 or 4;

V represents -(CH<sub>2</sub>)<sub>r</sub>; -A-(CH<sub>2</sub>)<sub>s</sub>-; -CH<sub>2</sub>-A-(CH<sub>2</sub>)<sub>t</sub>-; -(CH<sub>2</sub>)<sub>s</sub>-A-; -(CH<sub>2</sub>)<sub>2</sub>-A-(CH<sub>2</sub>)<sub>u</sub>-; -A-(CH<sub>2</sub>)<sub>v</sub>-B-; -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-A-CH<sub>2</sub>-; -A-CH<sub>2</sub>-CH<sub>2</sub>-B-CH<sub>2</sub>-; -CH<sub>2</sub>-A-CH<sub>2</sub>-CH<sub>2</sub>-B-CH<sub>2</sub>-; -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-A-CH<sub>2</sub>-CH<sub>2</sub>-; -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-A-CH<sub>2</sub>-; -A-CH<sub>2</sub>-CH<sub>2</sub>-B-CH<sub>2</sub>-CH<sub>2</sub>-; -CH<sub>2</sub>-A-CH<sub>2</sub>-CH<sub>2</sub>-B-CH<sub>2</sub>-; -CH<sub>2</sub>-A-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-B-; or -CH<sub>2</sub>-CH<sub>2</sub>-A-CH<sub>2</sub>-CH<sub>2</sub>-B-; -O-CH<sub>2</sub>-CH(OCH<sub>3</sub>)-CH<sub>2</sub>-O-; -O-CH<sub>2</sub>-CH(CH<sub>3</sub>)-CH<sub>2</sub>-O-; -O-CH<sub>2</sub>-CH(CF<sub>3</sub>)-CH<sub>2</sub>-O-;

15

A and B independently represent -O-; -S-; -SO-; -SO<sub>2</sub>-;

U represents aryl; heteroaryl;

20

T represents -CONR<sup>1</sup>-; -(CH<sub>2</sub>)<sub>p</sub>OCO-; -(CH<sub>2</sub>)<sub>p</sub>N(R<sup>1</sup>)CO-; -(CH<sub>2</sub>)<sub>p</sub>N(R<sup>1</sup>)SO<sub>2</sub>-; or

-COO-;

Q represents lower alkylene; lower alkenylene;

5 M represents hydrogen; cycloalkyl; aryl; heterocyclyl; heteroaryl;

R<sup>1</sup> represents hydrogen; lower alkyl; lower alkenyl; lower alkinyl; cycloalkyl; aryl; cycloalkyl - lower alkyl;

10 p is the integer 1, 2, 3 or 4;

r is the integer 3, 4, 5, or 6;

s is the integer 2, 3, 4, or 5;

t is the integer 1, 2, 3, or 4;

u is the integer 1, 2, or 3;

15 v is the integer 2, 3, or 4;

and optically pure enantiomers, mixtures of enantiomers such as racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, and the meso-form; as well as pharmaceutically acceptable salts, solvent complexes and morphological forms.

2. Compounds of general formula I wherein X, W, V, and U are as defined in general formula I and

25 T represents -CONR<sup>1</sup>;

Q represents methylene;

M represents hydrogen; aryl or heteroaryl;

and optically pure enantiomers, mixtures of enantiomers such as racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, and the meso-form; as well as pharmaceutically acceptable salts, solvent complexes and morphological forms.

3. Compounds of general formula I wherein X, W, U, T, Q, and M are as defined in general formula I and

5 V represents -CH<sub>2</sub>CH<sub>2</sub>O-; -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>O-; -OCH<sub>2</sub>CH<sub>2</sub>O-;

and optically pure enantiomers, mixtures of enantiomers such as racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, and the meso-form; as well as pharmaceutically acceptable salts, solvent complexes and morphological forms.

10 4. Compounds of general formula I wherein X, V, U, T, Q, and M are as defined in general formula I and

15 W represent a 1,4-disubstituted phenyl group;

and optically pure enantiomers, mixtures of enantiomers such as racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, and the meso-form; as well as pharmaceutically acceptable salts, solvent complexes and morphological forms.

20 5. Compounds of general formula I wherein X, W, V, Q, T, and M are as defined in general formula I and

25 U is a mono-, di-, or trisubstituted phenyl whereby the substituents are halogen; lower alkyl or lower alkoxy

and optically pure enantiomers, mixtures of enantiomers such as racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, and the meso-form; as well as pharmaceutically acceptable salts, solvent complexes and morphological forms.

6. The compounds according to any one of claims 1 - 5 selected from the group consisting of

(*rac.*)-(1*R*, 5*S*)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxa-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dimethylbenzyl)-amide,

(*rac.*)-(1*R*, 5*S*)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dimethylbenzyl)-amide, and

(*rac.*)-(1*R*, 5*S*)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3,3-dioxo-3*λ*<sup>6</sup>-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dimethylbenzyl)amide.

15 7. Pharmaceutical compositions containing a compound of any one of claims 1 to 6 and usual carrier materials and adjuvants for the treatment or prophylaxis of disorders which are associated with a dysregulation of the renin-angiotensin system (RAS), comprising cardiovascular and renal diseases hypertension, 20 congestive heart failure, pulmonary hypertension, cardiac insufficiency, renal insufficiency, renal or myocardial ischemia, atherosclerosis, renal failure, erectile dysfunction, glomerulonephritis, renal colic, glaucoma, diabetic complications, complications after vascular or cardiac surgery, restenosis, complications of treatment with immunosuppressive agents after organ transplantation, and other 25 diseases known to be related to the RAS.

30 8. A method for the treatment or prophylaxis of diseases which are related to the RAS comprising hypertension, congestive heart failure, pulmonary hypertension, cardiac insufficiency, renal insufficiency, renal or myocardial ischemia, atherosclerosis, renal failure, erectile dysfunction, glomerulonephritis, renal colic, glaucoma, diabetic complications, complications after vascular or cardiac surgery, restenosis, complications of treatment with immunosuppressive agents after organ

transplantation, and other diseases which are related to the RAS, which method comprises administrating a compound according to any one of claims 1 to 6 to a human being or animal.

- 5      9. The use of compounds according to any one of claims 1 to 6 for the treatment or prophylaxis of diseases which are associated with the RAS comprising hypertension, congestive heart failure, pulmonary hypertension, cardiac insufficiency, renal insufficiency, renal or myocardial ischemia, atherosclerosis, renal failure, erectile dysfunction, glomerulonephritis, renal colic, glaucoma, 10     diabetic complications, complications after vascular or cardiac surgery, restenosis, complications of treatment with immunosuppressive agents after organ transplantation, and other diseases known to be related to the RAS.
- 15     10. The use of one or more compounds of any one of claims 1 to 6 in combination with other pharmacologically active compounds comprising ACE inhibitors, angiotensin II receptor antagonists, endothelin receptor antagonists, vasodilators, calcium antagonists, potassium activators, diuretics, sympatholitics, beta-adrenergic antagonists, alpha-adrenergic antagonists, for the treatment of disorders as set forth in any one of claims 7 to 10.

ABSTRACT

The invention relates to novel 9-azabicyclo[3.3.1]nonene derivatives and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

**BLACK BORDERS**

**IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

**FADED TEXT OR DRAWING**

**BLURRED OR ILLEGIBLE TEXT OR DRAWING**

**SKEWED/SLANTED IMAGES**

**COLOR OR BLACK AND WHITE PHOTOGRAPHS**

**GRAY SCALE DOCUMENTS**

**LINES OR MARKS ON ORIGINAL DOCUMENT**

**REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

**OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**